Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus Dalgleish

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Idrugs : the Investigational Drugs Journal|July 21, 2007
Overcoming technical challenges in the development of cancer vaccinesAngus Dalgleish
Immunotherapy|December 21, 2016
Interview with Professor Angus DalgleishAngus Dalgleish
Current Opinion in Molecular Therapeutics|March 1, 2005
Novel immunotherapeutic approaches to prostate cancerAngus Dalgleish, Mike Whelan
Future Oncology (London, England)|October 6, 2010
The potential of immunomodulatory drugs in the treatment of solid tumorsAngus Dalgleish, Christine Galustian
Future Oncology (London, England)|August 5, 2017
The importance for immunoregulation for long-term cancer controlAlberto Fusi, Angus Dalgleish
Expert Opinion on Pharmacotherapy|February 25, 2009
Lenalidomide: a novel anticancer drug with multiple modalitiesChristine Galustian, Angus Dalgleish
International Reviews of Immunology|December 16, 2006
Overview of tumor cell-based vaccinesJohn Copier, Angus Dalgleish
Vaccine|August 8, 2007
Therapeutic cancer vaccinesStephen Ward, Angus Dalgleish
Hospital Medicine (London, England : 1998)|November 30, 2004
Melanoma vaccinesBruce Elliott, Angus Dalgleish
Current Opinion in Molecular Therapeutics|February 9, 2010
Whole-cell vaccines: A failure or a success waiting to happen?John Copier, Angus Dalgleish
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Idrugs : the Investigational Drugs Journal|July 21, 2007
Overcoming technical challenges in the development of cancer vaccinesAngus Dalgleish
Immunotherapy|December 21, 2016
Interview with Professor Angus DalgleishAngus Dalgleish
Current Opinion in Molecular Therapeutics|March 1, 2005
Novel immunotherapeutic approaches to prostate cancerAngus Dalgleish, Mike Whelan
Future Oncology (London, England)|October 6, 2010
The potential of immunomodulatory drugs in the treatment of solid tumorsAngus Dalgleish, Christine Galustian
Future Oncology (London, England)|August 5, 2017
The importance for immunoregulation for long-term cancer controlAlberto Fusi, Angus Dalgleish
Expert Opinion on Pharmacotherapy|February 25, 2009
Lenalidomide: a novel anticancer drug with multiple modalitiesChristine Galustian, Angus Dalgleish
International Reviews of Immunology|December 16, 2006
Overview of tumor cell-based vaccinesJohn Copier, Angus Dalgleish
Vaccine|August 8, 2007
Therapeutic cancer vaccinesStephen Ward, Angus Dalgleish
Hospital Medicine (London, England : 1998)|November 30, 2004
Melanoma vaccinesBruce Elliott, Angus Dalgleish
Current Opinion in Molecular Therapeutics|February 9, 2010
Whole-cell vaccines: A failure or a success waiting to happen?John Copier, Angus Dalgleish
Pageof 5